NUVB Stock — Nuvation Bio Inc.

Nuvation Bio Inc. (NUVB)

Updated October 16, 2026.

NUVB is a Stock. Total return is -55.5% over the past 6.1 years, 197.8 points behind SPY at 142.3%.

Nuvation Bio is a clinical-stage biopharmaceutical company developing cancer treatments, including its lead candidate IBTROZI (taletrectinib), a ROS1 inhibitor for ROS1-positive non-small cell lung cancer, and Safusidenib, an IDH1 inhibitor in phase 3 trials for certain brain tumors. The company does not currently distribute to shareholders. This security appeals to investors with a high risk tolerance seeking exposure to early-stage drug development, as clinical-stage biotech companies typically reinvest resources into research rather than generate near-term income.

NUVB performance versus SPY

Price and return data through 2026-10-16.

Total return is -55.5% over the past 6.1 years, 197.8 points behind SPY at 142.3%. Over the past year its total return — price change plus distributions reinvested — is 22.6%. Its deepest 1-year drawdown was 57.5%.

NUVB key facts

Asset type

Stock

Asset class

Equity

Inception date

08/24/2020

Distribution frequency

None

Last close

$4.45 (as of 2026-10-16)

Market cap

$1,558,048,387

Average volume

4470400.0

Beta

1.617

Payout ratio

0.0%

EPS

$-0.44

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NUVB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.5%.

Who may consider NUVB — and who may not

It is a weaker fit for investors who need monthly cash flow (NUVB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NUVB

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions